85 results on '"Koltowska-Häggström M"'
Search Results
2. Estrogen Replacement in Women of Fertile Years with Hypopituitarism
- Author
-
Mah, P M., Webster, J, Jönsson, P, Feldt-Rasmussen, U, Koltowska-Häggström, M, and Ross, R J. M.
- Published
- 2005
3. OR1-6: Combination medical therapy for acromegaly: the ACROSTUDY experience
- Author
-
Strasburger, C., primary, Hey-Hadavi, J., additional, Akerblad, A.-C., additional, Mattsson, A.F., additional, Koltowska-Häggström, M., additional, and Biller, B.M.K., additional
- Published
- 2014
- Full Text
- View/download PDF
4. Clinical Significance of Change in the Quality of Life-Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA) Score in Adult Growth Hormone Deficiency (AGHD)
- Author
-
Wiid, Z., primary, Pleil, A., additional, Ho, K., additional, Holdaway, I., additional, Cutfield, W., additional, Bullinger, M., additional, Koltowska-Häggström, M., additional, and Mardekian, J., additional
- Published
- 2013
- Full Text
- View/download PDF
5. Growth hormone replacement in adults with severe growth hormone deficiency is effective even if baseline IGF-1 levels are in the normal range
- Author
-
Faust, M, primary, Åkerblad, AC, additional, Buchfelder, M, additional, Johannsson, G, additional, Jonsson, P, additional, Kann, P, additional, Touraine, P, additional, and Koltowska Häggström, M, additional
- Published
- 2012
- Full Text
- View/download PDF
6. P02-49 Long-term outcomes of Pegvisomant (Somavert®) monotherapy: Cross-sectional observations from ACROSTUDY
- Author
-
van der Lely, A.J., primary, Brue, T., additional, Buchfelder, M., additional, Ghigo, E., additional, Gomez, R., additional, Hey-Hadavi, J., additional, Lundgren, F., additional, Rajicic, N., additional, Webb, S., additional, and Koltowska-Häggström, M., additional
- Published
- 2012
- Full Text
- View/download PDF
7. OR05-2 Pregnancies and live births in a large cohort of patients on growth hormone replacement therapy
- Author
-
Vila, G., primary, Åkerblad, A.-C., additional, Biller, B.M., additional, Koltowska-Häggström, M., additional, Lundgren, F., additional, Riedl, M., additional, and Luger, A., additional
- Published
- 2012
- Full Text
- View/download PDF
8. PDB72 FURTHER DEVELOPMENTS OF THE QUALITY OF LIFE ASSESSMENT OF GROWTH HORMONE DEFICIENCY IN ADULTS (QOL-AGHDA)
- Author
-
Twiss, J, primary, Mckenna, S, additional, Doward, L, additional, Hána, V, additional, Karbownik-Lewinska, M, additional, Popovic, V, additional, Pura, M, additional, Ribeiro-Oliveira, A, additional, and Koltowska-Häggström, M, additional
- Published
- 2010
- Full Text
- View/download PDF
9. From isolated GH deficiency to multiple pituitary hormone deficiency: an evolving continuum – a KIMS analysis
- Author
-
Klose, M, primary, Jonsson, B, additional, Abs, R, additional, Popovic, V, additional, Koltowska-Häggström, M, additional, Saller, B, additional, Feldt-Rasmussen, U, additional, and Kourides, I, additional
- Published
- 2009
- Full Text
- View/download PDF
10. Effect of Growth Hormone Replacement Therapy on Plasma Brain Natriuretic Peptide Concentration, Cardiac Morphology and Function in Adults with Growth Hormone Deficiency
- Author
-
Lazúrová, I., primary, Pura, M., additional, Wagnerová, H., additional, Tajtáková, M., additional, Sedláková, M., additional, Tomáš, L’., additional, Payer, J., additional, Hrúziková, P., additional, Vaňuga, P., additional, Podoba, J., additional, Trejbalová, L‘., additional, Popovic, V., additional, and Koltowska-Häggström, M., additional
- Published
- 2009
- Full Text
- View/download PDF
11. PDB38 THE COST-EFFECTIVENESS OF GROWTH HORMONE REPLACEMENTTHERAPY WITH GENOTROPIN® IN HYPOPITUITARY ADULT PATIENTS
- Author
-
Bolin, K, primary, Jonsson, B, additional, Koltowska-Häggström, M, additional, Prütz, C, additional, and Sandin, R, additional
- Published
- 2008
- Full Text
- View/download PDF
12. QL12 FRENCH NORMATIVE REFERENCE DATA FOR THE QUALITY OF LIFE ASSESSMENT OF GROWTH HORMONE DEFICIENCY IN ADULTS (QOL-AGHDA) QUESTIONNAIRE
- Author
-
Chachuat, A, primary, Koltowska-Häggström, M, additional, Gilet, H, additional, Auziere, S, additional, Guillaume, X, additional, Arnould, B, additional, and Viala-Danten, M, additional
- Published
- 2008
- Full Text
- View/download PDF
13. Baseline characteristics and response to GH replacement of hypopituitary patients previously irradiated for pituitary adenoma or craniopharyngioma: data from the Pfizer International Metabolic Database
- Author
-
Maiter, D, primary, Abs, R, additional, Johannsson, G, additional, Scanlon, M, additional, Jönsson, P J, additional, Wilton, P, additional, and Koltowska-Häggström, M, additional
- Published
- 2006
- Full Text
- View/download PDF
14. PO2-4: Pregnancy in acromegaly patients treated with pegvisomant
- Author
-
Van der Lely, A.J., Gomez, R., Heissler, J.F., Åkerblad, A.-C., Jönsson, P., Camacho-Hübner, C., and Kołtowska-Häggström, M.
- Published
- 2014
- Full Text
- View/download PDF
15. PPT2 THE DEFICIT IN HEALTH-RELATED QUALITY OF LIFE (HRQOL) FOR GROWTH HORMONE DEFICIENT (GHD) PATIENTS IN SPAIN AND ENGLAND & WALES: A COMPARISON WITH NORMATIVE POPULATION DATA
- Author
-
Mattsson, A, primary, Casanueva, F, additional, Espadero, R, additional, Badia, X, additional, Sanmarti, A, additional, Kind, P, additional, and Koltowska-Häggström, M, additional
- Published
- 2004
- Full Text
- View/download PDF
16. PPT7: IMPROVEMENT IN QUALITY OF LIFE AND HEALTHCARE UTILISATION DURING GROWTH HORMONE REPLACEMENT THERAPY IN HYPOPITUITARY ADULTS IN THE NETHERLANDS
- Author
-
den Hartog, M, primary, van Kuijck, MA, additional, Koppeschaar, HPF, additional, Mattsson, AF, additional, and Koltowska-Häggström, M, additional
- Published
- 2003
- Full Text
- View/download PDF
17. POD10 IMPROVEMENT IN QUALITY OF LIFE IN GROWTH HORMONE (GH) REPLACED HYPOPITUITARY ADULTS WITH GH DEFICIENCY IS CORRELATED WITH PATIENTREPORTED OUTCOMES:ANALYSIS OF THE KIMS DATABASE
- Author
-
Koltowska-Häggström, M, primary, Mattsson, A, additional, Svensson, J, additional, Johannsson, G, additional, and Rosen, T, additional
- Published
- 2002
- Full Text
- View/download PDF
18. PDB102 - Clinical Significance of Change in the Quality of Life-Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA) Score in Adult Growth Hormone Deficiency (AGHD)
- Author
-
Wiid, Z., Pleil, A., Ho, K., Holdaway, I., Cutfield, W., Bullinger, M., Koltowska-Häggström, M., and Mardekian, J.
- Published
- 2013
- Full Text
- View/download PDF
19. Incidence of diabetes mellitus and evolution of glucose parameters in growth hormone-deficient subjects during growth hormone replacement therapy: a long-term observational study.
- Author
-
Luger A, Mattsson AF, Koltowska-Häggström M, Thunander M, Góth M, Verhelst J, Abs R, Luger, Anton, Mattsson, Anders F, Koltowska-Häggström, Maria, Thunander, Maria, Góth, Miklos, Verhelst, Johan, and Abs, Roger
- Abstract
Objective: Growth hormone (GH) deficiency is associated with insulin resistance and diabetes. The aim of the current study was to determine incidence of diabetes during GH replacement therapy (GHRT) and the effect of GHRT on fasting plasma glucose concentrations and HbA(1c) in adult patients with GH deficiency.Research Design and Methods: A total of 5,143 GH-deficient patients (male 49.9%; mean age ± SD, 49 ± 13 years; BMI 29.1 ± 5.9 kg/m(2)) were analyzed. Mean observation period was 3.9 years (range 0.01-13). Total number of patient-years was 20,106. Observed number of cases (O) was compared with expected number of cases (E). Reference rates were from Sweden, three additional European regions, and one U.S. region.Results: Patients who developed diabetes (n = 523) were older; had higher BMI, waist circumference, triglyceride concentrations, and blood pressure; and had lower HDL-cholesterol concentrations (P < 0.0001) than those who did not develop diabetes. Diabetes incidence was 2.6 per 100 patient-years, equal in both sexes, and significantly increased compared with the Swedish reference (O/E = 6.02; P < 0.0001) as well as with the four other populations (O/E = 2.11-5.22). O/E increased with BMI and decreased with duration of GHRT (P < 0.0001). There was no significant association with GH dose (P = 0.74) or IGF-I SDS (P = 0.47). In subjects not developing diabetes, plasma glucose concentrations increased from 84.4 ± 0.9 mg/dL to 89.5 ± 0.8 mg/dL (0.70 mg/dL/year) and HbA(1c) increased from 4.74 ± 0.04% to 5.09 ± 0.13% (0.036%/year) after 6 years of GHRT.Conclusions: Diabetes incidence appears to be increased in GH-deficient patients receiving GHRT and exhibiting an adverse risk profile at baseline. Therefore, glucose homeostasis parameters should be monitored carefully in these patients. [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
20. Using EQ-5D to Derive General Population-based Utilities for the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA)
- Author
-
Koltowska-Häggström M, Jonsson B, Isacson D, and Bingefors K
- Published
- 2007
- Full Text
- View/download PDF
21. Comparison of factors influencing patient choice of community pharmacy in Poland and in the UK, and identification of components of pharmaceutical care
- Author
-
Merks P, Kaźmierczak J, Olszewska AE, and Kołtowska-Häggström M
- Subjects
Medicine (General) ,R5-920 - Abstract
Piotr Merks,1 Justyna Kazmierczak,2 Aleksandra Elzbieta Olszewska,3 Maria Koltowska-Häggström4 1Department of Pharmaceutical Care, Medical University of Warsaw, Poland; 2Department of Hygiene, Bioanalysis and Environmental Studies, Medical University of Silesia, Katowice, Poland; 3Department of Pharmacy, Ashford and St Peter’s Hospitals National Health Service Trust, Guildford Road, Chertsey, Surrey, United Kingdom; 4Department of Women’s and Children’s Health, Uppsala University, Uppsala, SwedenBackground: Several factors, which are components of pharmaceutical care, can influence a patient’s choice of a community pharmacy store and contribute to frequent visits to the same pharmacy.Objectives: To compare factors that influence a patient’s choice of pharmacy in Poland and in the UK, to identify which of them are components of pharmaceutical care, and to relate them to patient loyalty to the same pharmacy.Methods: A self-administered, anonymous questionnaire was distributed to clients visiting pharmacies in Poland and the UK January–August 2011. Comparisons were performed using chi-square tests and logistic regression. All statistical analyses were performed using SPSS 20.0.Results: The response rate was 55.6% (n=417/750; 36 pharmacies) and 54.0% (n=405/750; 56 pharmacies) in Poland and in the UK, respectively. The most frequently reported factors, as defined by a percentage of responders, were in Poland: 1) location (84%); 2) professional and high-quality of service (82%); 3) good price of medicines (78%); and 4) promotions on medicines (66%). In the UK, the most commonly reported factors were: 1) professional and high quality of service (90%); 2) location (89%); 3) good advice received from the pharmacist (86%); and 4) option of discussing and consulting all health issues in a consultation room (80%). Good advice and an option of discussing personal concerns with a pharmacist are components of pharmaceutical care. Thirty-eight percent of patients in Poland and 61% in the UK declared visiting the same pharmacy.Conclusion: Components of pharmaceutical care are important factors influencing the patient’s choice of pharmacy in the UK and, to a lesser degree, in Poland. Additionally, more patients in the UK than in Poland are committed to a single pharmacy. Therefore, implementing the full pharmaceutical care in Poland may contribute to an increase in patient loyalty and thus strengthen competitiveness of pharmacy businesses.Keywords: pharmacy choice, patient’s preferences, pharmaceutical care, patient-reported outcomes (PRO), health care system
- Published
- 2014
22. PDB102 Clinical Significance of Change in the Quality of Life-Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA) Score in Adult Growth Hormone Deficiency (AGHD)
- Author
-
Wiid, Z., Pleil, A., Ho, K., Holdaway, I., Cutfield, W., Bullinger, M., Koltowska-Häggström, M., and Mardekian, J.
- Full Text
- View/download PDF
23. Adaptation of the QoL-AGHDA scale for adults with growth hormone deficiency in four Slavic languages
- Author
-
McKenna Stephen P, Wilburn Jeanette, Twiss James, Crawford Sigrid R, Hána Václav, Karbownik-Lewinska Malgorzata, Popovic Vera, Pura Mikulas, and Koltowska-Häggström Maria
- Subjects
Adaptation ,Validation ,QoL-AGHDA ,Czech Republic ,Poland ,Serbia ,Slovakia ,Computer applications to medicine. Medical informatics ,R858-859.7 - Abstract
Abstract Purpose The Quality of Life in Adult Growth Hormone Deficiency Assessment (QoL-AGHDA) is a disease-specific quality of life measure specific to individuals who are growth hormone deficient. The present study describes the adaptation of the QoL-AGHDA for use in the following four Slavic languages; Czech, Polish, Serbian and Slovakian. Methods The study involved three stages in each language; translation, cognitive debriefing and validation. The validation stage assessed internal consistency (Cronbach's alpha), reproducibility (test-retest reliability using Spearman's rank correlations), convergent and divergent validity (Correlations with the NHP) and known group validity. Results The QoL-AGHDA was successfully translated into the target languages with minimal problems. Cognitive debriefing interviewees (n = 15-18) found the measures easy to complete and identified few problems with the content. Internal consistency (Czech Republic = 0.91, Poland = 0.91, Serbia = 0.91 and Slovakia = 0.89) and reproducibility (Czech Republic = 0.91, Poland = 0.91, Serbia = 0.88 and Slovakia = 0.93) were good in all adaptations. Convergent and divergent validity and known group validity data were not available for Slovakia. The QoL-AGHDA correlated as expected with the NHP scales most relevant to GHD. The QoL-AGHDA was able to distinguish between participants based on a range of variables. Conclusions The QoL-AGHDA was successfully adapted for use in the Czech Republic, Poland, Serbia and Slovakia. Further validation of the Slovakian version would be beneficial. The addition of these new lanaguage versions will prove valuable to multinational clinical trials and to clinical practice in the respective countries.
- Published
- 2011
- Full Text
- View/download PDF
24. Five-Year Postmarket Safety Experience With the Optimal Balance Technology Range of Hyaluronic Acid Fillers.
- Author
-
Jones DH, Bank D, Jacobsson J, Koltowska-Häggström M, and Wong C
- Subjects
- Humans, Product Surveillance, Postmarketing, Cosmetic Techniques adverse effects, Dermal Fillers adverse effects, Hyaluronic Acid adverse effects
- Published
- 2020
- Full Text
- View/download PDF
25. Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudy.
- Author
-
Brue T, Lindberg A, Jan van der Lely A, Akerblad AC, Koltowska-Häggström M, Gomez R, Droste M, Hey-Hadavi J, Strasburger CJ, and Camacho-Hübner C
- Subjects
- Acromegaly blood, Acromegaly complications, Adult, Diabetes Mellitus, Type 2 blood, Female, Human Growth Hormone pharmacology, Human Growth Hormone therapeutic use, Humans, Male, Middle Aged, Retrospective Studies, Acromegaly drug therapy, Blood Glucose drug effects, Diabetes Mellitus, Type 2 complications, Human Growth Hormone analogs & derivatives
- Abstract
Purpose: To explore the effects of pegvisomant (PEGV) on glucose metabolism in patients with acromegaly within ACROSTUDY, an international, observational, prospective safety surveillance study., Methods: Patients were retrospectively divided into two cohorts, with (DM group) or without diabetes mellitus (no-DM). Parameters of glucose metabolism and IGF-I values were analyzed yearly both cross-sectionally for 4 years (yrs) and longitudinally at 1 and 4-5 yrs of PEGV treatment., Results: Among 1762 patients, 510 (28.9%) had DM before PEGV start. At cross-sectional analyses, in the DM group mean blood glucose was 140.0 ± 58.7 mg/dl at baseline, 116.4 ± 44.8 mg/dl at year 1 and 120.0 ± 44.3 mg/dl at yr 4. Mean HbA1c was 6.6 ± 1.2 % at yr 1 vs. 7.0 ± 1.4 % at baseline. HbA1c was above 6.5% in 61.9% at baseline and ranged from 45.4 to 53.8% at subsequent yearly time points. At the 4-yr longitudinal analysis, in the DM group (n = 109), mean blood glucose decreased by 20.2 mg/dl at yr 4, mean HbA1c was 7.0 ± 1.5% at baseline vs. 6.8 ± 1.4%. Patients achieved IGF-I normalization in 52.1% and 57.4% of cases in the DM and no-DM groups, respectively at 1 year. The mean daily PEGV dose (mg/day) was higher in the DM group (18.2 vs. 15.3) while the absolute change of IGF-I values from baseline was similar in both groups. PEGV was well tolerated in both groups without any unexpected AEs., Conclusions: Patients with DM had a moderate decrease in mean fasting glucose values during PEGV treatment.
- Published
- 2019
- Full Text
- View/download PDF
26. Support Needs of Patients with Cushing's Disease and Cushing's Syndrome: Results of a Survey Conducted in Germany and the USA.
- Author
-
Kreitschmann-Andermahr I, Siegel S, Gammel C, Campbell K, Edwin L, Grzywotz A, Kuhna V, Koltowska-Häggström M, Müller O, Buchfelder M, and Kleist B
- Abstract
Background: Cushing's disease (CD) and Cushing's syndrome (CS) are chronic illnesses, characterized by symptoms of prolonged hypercortisolism, which often changes to hypocortisolism after successful treatment. In view of the high disease burden of CD/CS patients and long-term impaired quality of life, the present survey was conducted to gain information about subjective illness distress and patients' specific needs in terms of supportive measures beyond medical interventions., Patients and Methods: Cross-sectional questionnaire study including patients with CD treated in 2 German neurosurgical tertiary referral centers and CD/CS patient members of a US-based patient support group completed a survey inquiring about disease burden, coping strategies, and support needs. Additionally, the degree of interest in different offers, e.g., internet-based programs and seminars, was assessed., Results: 84 US and 71 German patients answered the questionnaire. Patients in both countries indicated to suffer from Cushing-related symptoms, reduced performance, and psychological problems. 48.8% US patients and 44.4% German patients stated that good medical care and competent doctors helped them the most in coping with the illness. US patients were more interested in support groups ( p = 0.035) and in courses on illness coping ( p = 0.008) than the German patients, who stated to prefer brochures ( p = 0.001). 89.3% of US patients would attend internet-based programs compared to 75.4% of German patients ( p = 0.040). There were no differences between groups for the preferred duration of and the willingness to pay for such a program, but US patients would travel longer distances to attend a support meeting ( p = 0.027)., Conclusion: Patients in both countries need skilled physicians and long-term medical care in dealing with the effects of CD/CS, whereas other support needs differ between patients of both countries. The latter implies that not only disease-specific but also culture-specific training programs would need to be considered to satisfy the needs of patients in different countries.
- Published
- 2018
- Full Text
- View/download PDF
27. Coping strategies have a strong impact on quality of life, depression, and embitterment in patients with Cushing's disease.
- Author
-
Siegel S, Milian M, Kleist B, Psaras T, Tsiogka M, Führer D, Koltowska-Häggström M, Honegger J, Müller O, Sure U, Menzel C, Buchfelder M, and Kreitschmann-Andermahr I
- Subjects
- Adaptation, Psychological, Adult, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Pituitary ACTH Hypersecretion surgery, Psychometrics, Quality of Life, Pituitary ACTH Hypersecretion psychology
- Abstract
Purpose: Quality of life (QoL) and psychosocial well-being are substantially impaired in patients with Cushing's disease (CD), not only at the acute illness stage but also after therapy; however, the reason for these impairments remains unclear., Methods: In this cross-sectional, patient-reported outcome study, we conducted a postal survey on psychosocial impairment and coping strategies in patients after surgical treatment of CD in three large tertiary referral centers. In total, 176 patients with CD completed a compilation of self-assessment inventories pertaining to depression (Hospital Anxiety and Depression Scale, HADS), QoL (Short Form SF-36, Tuebingen CD; Tuebingen CD-25), coping style (Freiburg questionnaire on coping with illness, FKV-LIS), and embitterment (Bern Embitterment Inventory), on average 6.8 ± 6.66 years after surgery. Regression analyses were performed to identify predictors of psychosocial impairment., Results: At the time of the study, 21.8 % of patients suffered from anxiety, 18.7 % experienced an above-average feeling of embitterment, and 13.1 % suffered from depression. Maladaptive coping styles (FKV-LIS subscales depressive coping and minimizing importance) emerged as robust and strong predictors of psychosocial impairment in all inventories; while age, sex, and hydrocortisone intake failed to explain the variance in these measures., Conclusion: Similar to several studies in non-pituitary patient cohorts (e.g., patients with multiple sclerosis or lower back pain), our results indicate that psychosocial impairment in CD is significantly influenced by how the patient deals with the illness. Therefore, psychological training of positive coping styles could be a helpful complementary therapy in the overall treatment strategy of CD.
- Published
- 2016
- Full Text
- View/download PDF
28. Diagnosis and management of acromegaly: the patient's perspective.
- Author
-
Kreitschmann-Andermahr I, Siegel S, Kleist B, Kohlmann J, Starz D, Buslei R, Koltowska-Häggström M, Strasburger CJ, and Buchfelder M
- Subjects
- Adenoma metabolism, Adult, Aftercare, Antineoplastic Agents therapeutic use, Cranial Irradiation, Female, Glucose Tolerance Test, Growth Hormone-Secreting Pituitary Adenoma metabolism, Human Growth Hormone metabolism, Humans, Hypophysectomy, Insulin-Like Growth Factor I metabolism, Magnetic Resonance Imaging, Male, Middle Aged, Patient Reported Outcome Measures, Patient Satisfaction, Sex Factors, Surveys and Questionnaires, Time Factors, Adenoma diagnosis, Adenoma therapy, Delayed Diagnosis statistics & numerical data, Growth Hormone-Secreting Pituitary Adenoma diagnosis, Growth Hormone-Secreting Pituitary Adenoma therapy, Referral and Consultation statistics & numerical data
- Abstract
Purpose: Early diagnosis is a success factor for the prevention of long-term comorbidity and premature death in patients with acromegaly, but large-scale data on the diagnostic process and disease management are scarce. Therefore, we aimed to evaluate the diagnostic process, implementation of treatment and changes in life situation in patients with acromegaly, focusing on sex-specific differences., Methods: Non-interventional patient-reported outcome study. 165 patients with clinically and biochemically proven acromegaly were questioned about the diagnostic process and utilization of health care by means of a self-developed standardized postal survey including questions on acromegaly symptoms experienced before diagnosis, number and specialty of consulted doctors, time to diagnosis and aftercare., Results: The diagnostic process took 2.9 (SD 4.53) years, during which 3.4 (SD 2.99) physicians were consulted. Women waited longer [4.1 (SD 5.53) years] than men [1.6 (SD 2.69) years; p = 0.001] for the correct diagnosis, and consulted more doctors in the process [4.0 (SD 2.99) vs. 2.7 (SD 2.84) doctors, p < 0.001, respectively]. In 48.5 % of patients, acromegaly was diagnosed by an endocrinologist (men: 45.1 %; women: 52.4 %). Overall disease duration from symptom onset until last surgery was 5.5 (SD 6.85) years, with no sex differences. A change in employment status was the most commonly reported event after diagnosis and a quarter of the patients stated that the illness had changed their lives., Conclusions: Our findings confirm the urgent need to increase awareness of the clinical manifestation of acromegaly to facilitate an earlier diagnosis of the disease and to provide diagnostic equality across the sexes.
- Published
- 2016
- Full Text
- View/download PDF
29. Is growth hormone treatment in children associated with weight gain?--longitudinal analysis of KIGS data.
- Author
-
Reinehr T, Lindberg A, Koltowska-Häggström M, and Ranke M
- Subjects
- Birth Weight drug effects, Body Height drug effects, Body Weight drug effects, Child, Child, Preschool, Female, Growth Disorders drug therapy, Humans, Infant, Newborn, Infant, Small for Gestational Age growth & development, Infant, Small for Gestational Age metabolism, Longitudinal Studies, Male, Human Growth Hormone therapeutic use, Prader-Willi Syndrome drug therapy, Turner Syndrome drug therapy, Weight Gain drug effects
- Abstract
Objective: Growth hormone (GH) increases lean body mass and reduces fat mass. However, the long-term changes in weight status during growth hormone treatment, according to age and weight status at onset of treatment, have not previously been reported in large data sets., Methods: Changes in BMI-SDS between starting GH treatment and attaining near adult height (NAH) were analysed in 2643 children with idiopathic GH deficiency (IGHD), 281 children small for gestational age (SGA), 1661 girls with Turner syndrome (TS), and 142 children with Prader-Willi syndrome (PWS) in the KIGS database., Results: BMI-SDS increased significantly between onset of GH treatment and NAH (IGHD:+0·29, SGA:+0·69, TS:+0·48) except in PWS (-0·02). These increases were greater in children with younger age at onset of GH treatment (significant in all indications) and with lower doses of GH treatment (significant in IGHD & TS) in multiple linear regression analyses also including gender, duration of GH treatment, BMI-SDS and height-SDS at onset of treatment, and birth weight-SDS. Obese children at onset of GH treatment decreased their BMI-SDS, while underweight and normal weight children at onset of GH treatment increased their BMI-SDS independently of GH treatment indication., Conclusions: Long-term GH treatment was associated with changes in weight status, which were beneficial for underweight and obese children independent of the indication for GH. However, the increase in BMI-SDS in normal weight children treated with GH needs to be investigated in future prospective longitudinal studies to analyse whether this represents an increase of fat mass, lean body mass or both., (© 2014 John Wiley & Sons Ltd.)
- Published
- 2014
- Full Text
- View/download PDF
30. The cost-effectiveness of growth hormone replacement therapy (Genotropin®) in hypopituitary adults in Sweden.
- Author
-
Bolin K, Sandin R, Koltowska-Häggström M, Loftus J, Prütz C, and Jonsson B
- Abstract
Background: To evaluate the cost-effectiveness of growth hormone (GH) treatment (Genotropin®) compared with no GH treatment in adults with GH deficiency in a Swedish societal setting., Methods: A Markov-type cost-utility simulation model was constructed and used to simulate, for men and women, morbidity and mortality for GH-treated and -untreated individuals over a 20-year period. The calculations were performed using current available prices concerning morbidity-related healthcare costs and costs for Genotropin®. All costs and treatment effects were discounted at 3%. Costs were expressed in Euro (1€ = 9.03 SEK). GH-treated Swedish patients (n = 434) were identified from the KIMS database (Pfizer International Metabolic Database) and untreated patients (n = 2135) from the Swedish Cancer Registry and the Hospital Discharge Registry., Results: The results are reported as incremental cost per quality-adjusted life year (QALY) gained, including both direct and indirect costs for GH-treated versus untreated patients. The weighted sum of all subgroup incremental cost per QALY was €15,975 and €20,241 for men and women, respectively. Including indirect cost resulted in lower cost per QALY gained: €11,173 and €10,753 for men and women, respectively. Key drivers of the results were improvement in quality of life, increased survival, and intervention cost., Conclusions: The incremental cost per QALY gained is moderate when compared with informal thresholds applied in Sweden. The simulations suggest that GH-treatment is cost-effective for both men and women at the €55,371 (SEK 500,000 - the informal Swedish cost-effectiveness threshold) per QALY threshold.
- Published
- 2013
- Full Text
- View/download PDF
31. Clinical characteristics and effects of GH replacement therapy in adults with childhood-onset craniopharyngioma compared with those in adults with other causes of childhood-onset hypothalamic-pituitary dysfunction.
- Author
-
Yuen KC, Koltowska-Häggström M, Cook DM, Fox JL, Jönsson PJ, Geffner ME, and Abs R
- Subjects
- Adenoma complications, Adenoma surgery, Adenoma therapy, Adolescent, Adult, Age of Onset, Child, Craniopharyngioma surgery, Craniopharyngioma therapy, Female, Human Growth Hormone deficiency, Humans, Hypopituitarism physiopathology, Hypothalamo-Hypophyseal System physiopathology, Longitudinal Studies, Male, Pituitary Neoplasms surgery, Pituitary Neoplasms therapy, Quality of Life, Retrospective Studies, Social Behavior, Young Adult, Craniopharyngioma complications, Human Growth Hormone therapeutic use, Hypopituitarism drug therapy, Hypopituitarism etiology, Pituitary Neoplasms complications
- Abstract
Objective: Adults with childhood-onset (CO) craniopharyngioma (COCP) have poor quality of life (QoL) and clinical outcomes, but few studies have compared these patients with adults with other causes of CO hypothalamic-pituitary dysfunction. In this study, we compared baseline clinical characteristics and patient-reported outcomes before starting GH replacement therapy in adults with GH deficiency (GHD) due to COCP with those of adults either with CO idiopathic/congenital hypopituitarism (COH) or with CO extrasellar (COE) tumours, and evaluated the 1- and 5-year effects of GH replacement therapy., Subjects and Methods: Retrospective analysis of the data recorded in KIMS (Pfizer International Metabolic Database) was carried out. Patients with COCP, COH and COE tumours were evaluated at baseline, and after 1 and 5 years of therapy., Results: Compared with COH and COE patients, more COCP patients underwent surgery, had greater abnormalities of body composition and higher prevalence of pituitary hormone deficits (all P<0.001), but comparable fasting glucose, HbA1c, total cholesterol and LDL-cholesterol levels, marital status, parenthood, living arrangements, education, employment and annual sick-leave days. After 1 and 5 years of GH replacement therapy, similar changes were evident with regard to body composition, fasting glucose and HbA1c levels, QoL, and the level of and satisfaction with physical activity across the three groups., Conclusions: Adults with untreated COCP with GHD at baseline demonstrated more co-morbidities including greater abnormalities of body composition, pituitary hormone deficits and visual field defects. Overall, adults with COCP, COH and COE tumours responded comparably to short- and long-term GH replacement therapy, suggesting that patients with GHD due to COCP benefited from GH replacement therapy to a similar degree as those with other causes of CO hypothalamic-pituitary dysfunction did.
- Published
- 2013
- Full Text
- View/download PDF
32. Magnetic resonance imaging of CNS in 15,043 children with GH deficiency in KIGS (Pfizer International Growth Database).
- Author
-
Maghnie M, Lindberg A, Koltowska-Häggström M, and Ranke MB
- Subjects
- Adolescent, Child, Child, Preschool, Databases, Factual, Female, Humans, Magnetic Resonance Imaging, Male, Neuroimaging, Human Growth Hormone deficiency, Pituitary Diseases pathology, Pituitary Gland pathology
- Abstract
Objectives: Neuroimaging has become an essential part of the diagnostic process in children with GH deficiency (GHD). The aim of the study was to document the frequency of neuroanatomical abnormalities in a very large cohort of children with GHD and to relate these findings to patient clinical characteristics., Design and Methods: Results of magnetic resonance imaging (MRI) were reported in 15,043 of 43,725 children with non-acquired GHD (idiopathic, neurosecretory dysfunction (NSD) and known congenital cause) who were enrolled in KIGS (Pfizer International Growth Database) between 1987 and 2011. Clinical characteristics of patients before GH treatment with normal MRI (idiopathic GHD (IGHD) and NSD) were compared with those of patients with abnormal pituitaries (hypoplasia, empty sella (ES), HME (hypoplastic anterior pituitary, missing pituitary stalk and ectopic posterior pituitary))., Results: Abnormal MRIs were found in 4032 (26.8%) children, within which ES (N=1178 (7.8%)) and HME (N=1019 (6.8%)) were the most frequent findings. In 2361 children diagnosed as IGHD or NSD before MRI examination, anatomical abnormalities ((pituitary hypoplasia: n=974); (HME: n=459)) were documented. Patients with anatomical abnormalities had more severe characteristics of GHD: normal MRI < pituitary hypoplasia < ES < HME., Conclusions: GHD is associated with a great variety of neuroanatomical abnormalities as identified by MRI. The investigation and evaluation of MRI need to be conducted in a structured mode. There is an association between anatomical and functional abnormalities of the pituitary.
- Published
- 2013
- Full Text
- View/download PDF
33. The metabolic consequences of thyroxine replacement in adult hypopituitary patients.
- Author
-
Filipsson Nyström H, Feldt-Rasmussen U, Kourides I, Popovic V, Koltowska-Häggström M, Jonsson B, and Johannsson G
- Subjects
- Adult, Female, Glycated Hemoglobin metabolism, Human Growth Hormone deficiency, Humans, Male, Middle Aged, Hypopituitarism drug therapy, Hypopituitarism metabolism, Thyroxine therapeutic use
- Abstract
The metabolic consequences of thyroxine replacement in patients with central hypothyroidism (CH) need to be evaluated. The aim was to examine the outcome of thyroxine replacement in CH. Adult hypopituitary patients (n = 1595) with and without CH from KIMS (Pfizer International Metabolic Database) were studied before and after 2 years of GH replacement. CH patients (CH, n = 1080) were compared with TSH sufficient patients (TSHsuff n = 515) as one group and divided by thyroxine dose/kg/day into tertiles (CHlow-mid-high). Anthropometry, fasting glucose, glycosylated haemoglobin (HbA1c), blood pressure, lipids, IGF-I SDS, quality of life and morbidity were studied. Analyses were standardized for gender, age, number and types of pituitary insufficiencies, stimulated GH peak, age at GH deficiency onset, aetiologies and, when appropriate, for weight and GH dose. At baseline, TSHsuff patients did not differ from CH or CHmid in any outcome. CHlow (≤ 1.18 μg thyroxine/kg/day) had increased weight, BMI and larger waist circumference (WC), CHhigh (≥ 1.58 μg thyroxine/kg/day) had lower weight, BMI, WC and IGF-I than TSHsuff and compared to their predicted weights, BMIs and WCs. For every 0.1 μg/kg/day increase of thyroxine dose, body weight decreased 1.0 kg, BMI 0.3 kg/m(2), and WC 0.65 cm. The GH sensitivity of the CH group was higher (0.76 ± 0.56 SDS/mg GH) than that of TSHsuff patients (0.58 ± 0.64 SDS/mg GH), P < 0.001. The middle thyroxine dose (1.19-1.57 μg/kg/day) seems to be the most physiological. This is equivalent to 70, 100, 125 μg thyroxine/day for hypopituitary patients of 50, 70 or 90 kg weight, respectively.
- Published
- 2012
- Full Text
- View/download PDF
34. Overall and cause-specific mortality in GH-deficient adults on GH replacement.
- Author
-
Gaillard RC, Mattsson AF, Akerblad AC, Bengtsson BÅ, Cara J, Feldt-Rasmussen U, Koltowska-Häggström M, Monson JP, Saller B, Wilton P, and Abs R
- Subjects
- Adult, Aged, Female, Human Growth Hormone administration & dosage, Humans, Hypopituitarism drug therapy, Hypopituitarism etiology, Insulin-Like Growth Factor I metabolism, Male, Middle Aged, Poisson Distribution, Hormone Replacement Therapy adverse effects, Human Growth Hormone adverse effects, Human Growth Hormone deficiency, Hypopituitarism mortality
- Abstract
Objective: Hypopituitarism is associated with an increased mortality rate but the reasons underlying this have not been fully elucidated. The purpose of this study was to evaluate mortality and associated factors within a large GH-replaced population of hypopituitary patients., Design: In KIMS (Pfizer International Metabolic Database) 13,983 GH-deficient patients with 69,056 patient-years of follow-up were available., Methods: This study analysed standardised mortality ratios (SMRs) by Poisson regression. IGF1 SDS was used as an indicator of adequacy of GH replacement. Statistical significance was set to P<0.05., Results: All-cause mortality was 13% higher compared with normal population rates (SMR, 1.13; 95% confidence interval, 1.04-1.24). Significant associations were female gender, younger age at follow-up, underlying diagnosis of Cushing's disease, craniopharyngioma and aggressive tumour and presence of diabetes insipidus. After controlling for confounding factors, there were statistically significant negative associations between IGF1 SDS after 1, 2 and 3 years of GH replacement and SMR. For cause-specific mortality there was a negative association between 1-year IGF1 SDS and SMR for deaths from cardiovascular diseases (P=0.017) and malignancies (P=0.044)., Conclusions: GH-replaced patients with hypopituitarism demonstrated a modest increase in mortality rate; this appears lower than that previously published in GH-deficient patients. Factors associated with increased mortality included female gender, younger attained age, aetiology and lower IGF1 SDS during therapy. These data indicate that GH replacement in hypopituitary adults with GH deficiency may be considered a safe treatment.
- Published
- 2012
- Full Text
- View/download PDF
35. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY.
- Author
-
van der Lely AJ, Biller BM, Brue T, Buchfelder M, Ghigo E, Gomez R, Hey-Hadavi J, Lundgren F, Rajicic N, Strasburger CJ, Webb SM, and Koltowska-Häggström M
- Subjects
- Acromegaly etiology, Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Female, Follow-Up Studies, Hormone Antagonists therapeutic use, Human Growth Hormone adverse effects, Human Growth Hormone therapeutic use, Humans, Infant, Liver Function Tests, Male, Middle Aged, Pituitary Neoplasms complications, Product Surveillance, Postmarketing, Treatment Outcome, Acromegaly drug therapy, Hormone Antagonists adverse effects, Human Growth Hormone analogs & derivatives, Pituitary Neoplasms drug therapy, Receptors, Somatotropin antagonists & inhibitors
- Abstract
Context: Pegvisomant is a GH receptor antagonist. The ACROSTUDY is a global safety surveillance study of long-term treatment of acromegaly with pegvisomant., Objective: The objective of the study was to monitor long-term safety and treatment outcomes., Design: ACROSTUDY is open to all patients with acromegaly who are treated with pegvisomant. We report an interim analysis of data captured from 1288 subjects enrolled before a database freeze of December 31, 2009., Setting: This was a global noninterventional surveillance study., Main Outcome Measure(s): Long-term monitoring of safety, including central magnetic resonance imaging (MRI) reading and treatment outcomes, was measured., Results: Subjects (n = 1288) were treated with pegvisomant for a mean of 3.7 yr and followed up in ACROSTUDY for a mean of 2.1 yr. A total of 1147 adverse events (AE) were recorded in 477 subjects (37%), among which 192 AE in 124 subjects (9.6%) were considered to be related to pegvisomant. Serious AE were recorded in 159 subjects (12.3%), whereas pegvisomant-related Serious AE were recorded in 26 subjects (2%). No deaths (15 subjects; 1.2%) were attributed to pegvisomant use. The incidence of increase in pituitary tumor size in the subset with confirmed MRI increases on central reading represented 3.2% of the overall cohort with at least two available MRI (n = 936). Injection-site reactions were reported in 28 cases (2.2%). In 30 patients (2.5%), an elevated aspartate aminotransferase or alanine aminotransferase of more than 3 times the upper level of normality was reported. There were no reports of liver failure. After 5 yr of pegvisomant treatment, 63.2% of subjects had normal IGF-I levels at a mean dose of 18 mg/d., Conclusions: Data entered and evaluated in ACROSTUDY indicate that pegvisomant is an effective and safe medical treatment in patients with acromegaly. The reported low incidence of pituitary tumor size increase, liver enzyme elevations, and lipodystrophy at the injection site are reassuring.
- Published
- 2012
- Full Text
- View/download PDF
36. Comorbidity and cardiovascular risk factors in adult GH deficiency following treatment for Cushing's disease or non-functioning pituitary adenomas during childhood.
- Author
-
Ragnarsson O, Höybye C, Jönsson PJ, Feldt-Rasmussen U, Johannsson G, Biller BM, and Koltowska-Häggström M
- Subjects
- Adenoma complications, Adolescent, Adult, Age of Onset, Child, Comorbidity, Female, Humans, Male, Middle Aged, Pituitary ACTH Hypersecretion complications, Pituitary Neoplasms complications, Retrospective Studies, Risk Factors, Young Adult, Adenoma epidemiology, Cardiovascular Diseases epidemiology, Cardiovascular Diseases etiology, Human Growth Hormone deficiency, Pituitary ACTH Hypersecretion epidemiology, Pituitary Neoplasms epidemiology
- Abstract
Objective: Cushing's disease (CD) and non-functioning pituitary adenoma (NFPA) are rare in paediatric patients. The aim of this study was to describe long-term consequences in adults with GH deficiency (GHD) treated for CD or NFPA during childhood., Design, Patients and Methods: This was a retrospective analysis of data from KIMS (Pfizer International Metabolic Database). Background characteristics, anthropometry and comorbidity were studied in 47 patients diagnosed with childhood-onset (CO)-CD and 62 patients with CO-NFPA. Data from 100 ACTH-sufficient patients with CO-idiopathic hypopituitarism (CO-Idio) were used for comparison. Cardiovascular risk profile was analysed at baseline and at 1 year on GH treatment in a subgroup of patients (17 CO-CD, 24 CO-NFPA and 55 CO-Idio) not receiving GH treatment at study entry., Results: The median age at diagnosis of pituitary tumour was 14.0 years (range 10-17) in patients with CO-CD and 13.7 years (range 8-17) in CO-NFPA. In addition to GHD, 41% of patients with CO-CD had three or four other pituitary hormone deficiencies compared with 78% of patients with CO-NFPA (P<0.001). Eighty-nine per cent of patients with CO-CD had height SDS lower than 0 compared with 61% of patients with CO-NFPA (P=0.002). Hypertension was more common in CO-CD compared with CO-Idio (23 vs 9%, P=0.018). At 1 year on GH treatment, total- and low-density lipoprotein-cholesterol decreased significantly in CO-CD but not in CO-NFPA., Conclusion: Adult patients with GHD following treatment for paediatric CD and NFPA have long-term adverse consequences. Despite more severe hypopituitarism in CO-NFPA, patients with CO-CD have more frequently compromised final stature.
- Published
- 2012
- Full Text
- View/download PDF
37. GH deficiency during the transition period: clinical characteristics before and after GH replacement therapy in two different subgroups of patients.
- Author
-
Fideleff HL, Jonsson B, Koltowska-Häggström M, Boguszewski MC, Wilton P, and Boquete HR
- Subjects
- Adolescent, Adult, Age of Onset, Female, Humans, Male, Quality of Life, Regression Analysis, Hormone Replacement Therapy, Human Growth Hormone deficiency
- Abstract
Objective: To study two subsets of patients with GH deficiency (GHD) during the transition period: childhood onset GHD (CO-GHD) and patients who develop GHD during the transition phase (TO-GHD) before and after GH replacement., Patients and Measurements: In 1340 GHD subjects from KIMS (Pfizer International Metabolic Database), CO (n=586) or TO (n=754), background characteristics, anthropometric measurements, IGF-1, lipids and quality of life (QoL) were evaluated at baseline and after 3 years of GH replacement., Results: Both groups responded similarly to GH treatment. Changes of clinical outcomes were mainly determined by their value at baseline. Onset of the disease in childhood or transition period did not appear to be a significant predictor of response in any of the clinical outcomes., Conclusions: Age at GHD diagnosis was a significant predictor for many outcomes at baseline, but disease onset did not appear as an independent predictor concerning changes after 3 years of GH treatment. The results suggest that GH replacement during the transition period should be considered independently of the onset of the deficiency.
- Published
- 2012
- Full Text
- View/download PDF
38. Prevalence and characteristics of the metabolic syndrome in 2479 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis.
- Author
-
Verhelst J, Mattsson AF, Luger A, Thunander M, Góth MI, Koltowska-Häggström M, and Abs R
- Subjects
- Adult, Age Factors, Cohort Studies, Female, Human Growth Hormone blood, Human Growth Hormone therapeutic use, Humans, Hypopituitarism blood, Hypopituitarism diagnosis, Male, Metabolic Syndrome blood, Middle Aged, Prevalence, Hormone Replacement Therapy methods, Human Growth Hormone deficiency, Hypopituitarism epidemiology, Metabolic Syndrome diagnosis, Metabolic Syndrome epidemiology
- Abstract
Objective: An increased risk of cardiovascular morbidity and mortality in adult GH deficiency (GHD) may be related to hypopituitarism but also to the presence of the metabolic syndrome (MetS). Our objective was to investigate the characteristics and prevalence of MetS as well as its comorbidities in adult GHD. Design In KIMS (Pfizer International Metabolic Database) 2479 patients with severe adult-onset GHD, naïve to GH replacement, with complete information on all MetS components were found. MetS was defined according to the National Cholesterol Education Program's Adult Treatment Panel III (NCEP) and the International Diabetes Foundation (IDF)., Methods: The prevalence of MetS was calculated and compared with previously published data from the normal population. Associations were assessed between background variables, baseline variables, comorbidities, and MetS., Results: MetS was present in 43.1% (NCEP) and in 49.1% (IDF) of patients, clearly higher than data from the normal population (20-30%). MetS prevalence was related to age, GHD duration, and body mass index (BMI), but not to GHD severity, extent of hypopituitarism, or etiology of pituitary disease. Adjusted for age, gender, and BMI, patients with MetS had a higher prevalence ratio for diabetes mellitus: 4.65 (95% confidence interval (CI): 3.29-6.58), for cardiovascular morbidity: 1.91 (95% CI: 1.33-2.75), and for cerebrovascular morbidity: 1.77 (95% CI: 1.09-2.87) than patients without MetS., Conclusions: MetS is highly prevalent in GHD and is associated with a higher prevalence ratio for comorbidities. The presence of MetS in GHD may therefore contribute to the increased risk of cardiovascular morbidity and mortality found in these patients.
- Published
- 2011
- Full Text
- View/download PDF
39. Prediction of improvement in quality of life (QoL-AGHDA) in adults with growth hormone deficiency by normative reference limits: data of the German KIMS cohort.
- Author
-
Moock J, Friedrich N, Völzke H, Spielhagen C, Nauck M, Koltowska-Häggström M, Buchfelder M, Wallaschofski H, and Kohlmann T
- Subjects
- Adult, Age Factors, Aged, Aged, 80 and over, Cohort Studies, Databases as Topic, Female, Germany, Growth Hormone therapeutic use, Humans, Male, Middle Aged, Predictive Value of Tests, ROC Curve, Reference Standards, Retrospective Studies, Sex Factors, Surveys and Questionnaires, Growth Hormone deficiency, Quality of Life
- Abstract
Objective: The objective of the present study was to calculate sex- and age-specific normative values for health-related quality of life (HRQoL) in Germany using quantile regression. Furthermore, we investigate the estimates of these normative data to and to predict the improvement of QoL-AGHDA scores in the German KIMS cohort during growth hormone treatment., Design: Normative data of HRQoL was assessed by quality of life assessment of growth hormone deficiency (GHD) in adults (QoL-AGHDA) in a representative sample of the German population (n=4172). Corresponding data for 888 patients with GHD were retrieved from the German KIMS cohort (Pfizer International Metabolic Database)., Results: The overall mean QoL-AGHDA score of the general population was 4.8±5.2. ANOVA indicated that variability in QoL-AGHDA scores did not differ significantly across gender (p=0.20), whereas age was a significant predictor (p<0.001). Given the QoL-AGHDA score distribution of the general population, we calculated reference values based on quantile regression. In KIMS patients we observed significantly higher QoL-AGHDA scores, 7.9±6.5 (p<0.001), before GH treatment. The optimal predictive QoL-AGHDA score was 6 (70th percentile) with a sensitivity of 0.57 and a specificity of 0.70 in ROC analysis. Furthermore, a baseline QoL-AGHDA score above the 70th percentile allowed predicting an improvement of QoL by GH treatment., Conclusions: This study established normative reference values for the QoL-AGHDA in a representative sample of the German population. Based on these normative data a QoL-AGHDA cut-off value for prediction of improvement was investigated for the German population, which may facilitate clinical assessment of HRQoL response to GH replacement for patients with GHD., (Copyright © 2011 Elsevier Ltd. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
40. Serum insulin-like growth factor I (IGF-I), IGF-binding proteins 2 and 3, and the risk for development of malignancies in adults with growth hormone (GH) deficiency treated with GH: data from KIMS (Pfizer International Metabolic Database).
- Author
-
Popovic V, Mattsson AF, Gaillard RC, Wilton P, Koltowska-Häggström M, and Ranke MB
- Subjects
- Adult, Aged, Case-Control Studies, Databases, Factual, Drug Industry, Female, Hormone Replacement Therapy, Human Growth Hormone blood, Human Growth Hormone deficiency, Humans, Hypopituitarism blood, Hypopituitarism complications, Hypopituitarism epidemiology, International Cooperation, Male, Middle Aged, Neoplasms blood, Neoplasms epidemiology, Risk, Human Growth Hormone therapeutic use, Hypopituitarism drug therapy, Insulin-Like Growth Factor Binding Protein 2 blood, Insulin-Like Growth Factor Binding Protein 3 blood, Insulin-Like Growth Factor I analysis, Neoplasms etiology
- Abstract
Context: The association between IGFs and cancer in adults with GH deficiency (GHD) receiving GH replacement requires investigation., Objective: The objective was to examine the association between IGF-I, IGF-binding protein 2 (IGFBP-2), and IGFBP-3 SD scores (SDSs) in GH-deficient adults receiving GH therapy and the occurrence of de novo malignancies., Design: Serum IGF-I, IGFBP-2, and IGFBP-3 levels in GH-deficient patients who developed a malignancy since receiving GH were compared with patients with idiopathic GHD but without malignancy. Measurements were related to age-, sex-, and body mass index-specific SDS reference regions., Setting: The setting included the KIMS (the Pfizer International Metabolic Database)., Patients: One hundred patients with de novo malignancy during GH therapy were compared with 325 patients with idiopathic GHD without malignancy., Intervention(s): Serum samples were obtained as close as possible to the diagnosis of malignancy, or after approximately 2 yr of GH replacement in KIMS., Main Outcome Measures: Associations between relative risk (RR) of malignancy and IGF-I, IGFBP-2, and IGFBP-3 SDSs were assessed in multiple log-linear Poisson working regression models, controlling for age, sex, onset of GHD, and GH naivety at KIMS entry., Results: No association between IGF-I SDSs and RR was observed (P = 0.48). Increasing IGFBP-2 and IGFBP-3 SDSs were associated with increasing RRs [18% per unit IGFBP-2 SDSs (95% confidence interval, 7-30%; P = 0.0006), 13% per unit IGFBP-3 SDS (2-26%; P = 0.01)]., Conclusions: IGF-I levels targeted to within normal age-related reference ranges during GH replacement were not associated with the occurrence of malignancies. Higher IGFBP-2 and/or IGFBP-3 SDSs may be associated with increased cancer risk.
- Published
- 2010
- Full Text
- View/download PDF
41. The pituitary gland and age-dependent regulation of body composition.
- Author
-
van Beek AP, Wolffenbuttel BH, Runge E, Trainer PJ, Jönsson PJ, and Koltowska-Häggström M
- Subjects
- Adult, Age Factors, Aged, Aged, 80 and over, Body Mass Index, Chi-Square Distribution, Databases, Factual, Female, Human Growth Hormone deficiency, Humans, Hypopituitarism complications, Hypopituitarism drug therapy, Immunoassay, Male, Middle Aged, Obesity complications, Waist Circumference, Body Composition, Hypopituitarism physiopathology, Obesity physiopathology, Pituitary Gland physiopathology
- Abstract
Context: The prevalence of obesity is increased in hypopituitarism. In the general population, body mass index (BMI) and waist circumference increase with advancing age. It remains uncertain whether age-related changes in pituitary function contribute to the changes in body composition associated with advancing years., Objective: Our objective was to study the relationship between pituitary function, body composition, and age in a large cohort of patients with hypopituitarism and a matched reference population., Design, Setting, and Participants: A total of 3632 GH-deficient adults with hypopituitarism, adequately replaced with all pituitary hormones except for GH, from the prospective KIMS database (Pfizer International Metabolic Database) were included in present analysis. A random sample of the general population (3427 subjects) was used as reference. Patients and controls were grouped by gender in five age cohorts of 10 yr from 28 yr onward., Main Outcome Measures: Differences in BMI and waist circumference were evaluated., Results: Patients had a significantly higher BMI and waist circumference than controls, with larger differences at younger age. With advancing age, an increase in BMI and waist circumference was seen in controls but was virtually absent in the patients with adult-onset GH deficiency and hypopituitarism., Conclusion: Patients with hypopituitarism have more excess body fat than age-matched controls, especially in the youngest age groups. The normal increase in fat mass with advancing age is not seen in adult-onset GH-deficient hypopituitarism, suggesting a potential role for the normal pituitary gland as an age-dependent regulator of body composition in adult life.
- Published
- 2010
- Full Text
- View/download PDF
42. Application of the disease-specific Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA) questionnaire in a general population: results from a French panel study.
- Author
-
Gilet H, Chachuat A, Viala-Danten M, Auzière S, and Koltowska-Häggström M
- Subjects
- Adolescent, Adult, Aged, Female, France, Humans, Male, Middle Aged, Psychometrics, Reference Values, Reproducibility of Results, Dwarfism, Pituitary, Health Status, Quality of Life, Surveys and Questionnaires
- Abstract
Objectives: To assess the psychometric properties of the disease-specific Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA) questionnaire in a general population, and collect French normative data., Methods: A postal survey was conducted on 2900 adult panelists representative of the French population. The participants were asked to complete a questionnaire including the QoL-AGHDA and an evaluation of their overall health status (OHS). The QoL-AGHDA score ranges from 0 to 25, a lower score indicating better QoL. Psychometric properties of the QoL-AGHDA were assessed. The mean QoL-AGHDA scores were described by sex and age groups., Results: The return rate was 75%. The quality of completion and internal consistency reliability were good: 95% of the respondents completed all 25 QoL-AGHDA items and Cronbach's alpha was 0.86. The QoL-AGHDA score was able to discriminate between the respondents according to their OHS (from 1.5 for excellent to 12.3 for poor OHS, P < 0.001). The mean QoL-AGHDA score was 4.6 for the overall population, 5.1 for females and 4.2 for males, and ranged from 4.8 for the youngest to 6.1 for the oldest respondents., Conclusions: The QoL-AGHDA questionnaire showed good psychometric properties when administered in the French population. French reference values were collected, completing the QoL-AGHDA normative database already available in several European countries.
- Published
- 2010
- Full Text
- View/download PDF
43. Clinical features of GH deficiency and effects of 3 years of GH replacement in adults with controlled Cushing's disease.
- Author
-
Höybye C, Ragnarsson O, Jönsson PJ, Koltowska-Häggström M, Trainer P, Feldt-Rasmussen U, and Biller BM
- Subjects
- Adenoma blood, Adult, Blood Glucose metabolism, Blood Pressure, Body Mass Index, Cholesterol blood, Cohort Studies, Cross-Sectional Studies, Female, Glycated Hemoglobin metabolism, Humans, Insulin-Like Growth Factor I metabolism, Longitudinal Studies, Male, Middle Aged, Pituitary ACTH Hypersecretion blood, Pituitary Neoplasms blood, Quality of Life, Retrospective Studies, Statistics, Nonparametric, Adenoma therapy, Human Growth Hormone administration & dosage, Human Growth Hormone deficiency, Pituitary ACTH Hypersecretion therapy, Pituitary Neoplasms therapy
- Abstract
Objective: Patients in remission from Cushing's disease (CD) have many clinical features that are difficult to distinguish from those of concomitant GH deficiency (GHD). In this study, we evaluated the features of GHD in a large cohort of controlled CD patients, and assessed the effect of GH treatment., Design and Methods: Data were obtained from KIMS, the Pfizer International Metabolic Database. A retrospective cross-sectional comparison of background characteristics in unmatched cohorts of patients with CD (n=684, 74% women) and nonfunctioning pituitary adenoma (NFPA; n=2990, 39% women) was conducted. In addition, a longitudinal evaluation of 3 years of GH replacement in a subset of patients with controlled CD (n=322) and NFPA (n=748) matched for age and gender was performed., Results: The cross-sectional study showed a significant delay in GHD diagnosis in the CD group, who had a higher prevalence of hypertension, fractures, and diabetes mellitus. In the longitudinal, matched study, the CD group had a better metabolic profile but a poorer quality of life (QoL) at baseline, which was assessed with the disease-specific questionnaire QoL-assessment of GHD in adults. After 3 years of GH treatment (mean dose at 3 years 0.39 mg/day in CD and 0.37 mg/day in NFPA), total and low-density lipoprotein cholesterol decreased, while glucose and HbAlc increased. Improvement in QoL was observed, which was greater in the CD group (-6 CD group versus -5 NFPA group, P<0.01)., Conclusion: In untreated GHD, co-morbidities, including impairment of QoL, were more prevalent in controlled CD. Overall, both the groups responded similarly to GH replacement, suggesting that patients with GHD due to CD benefit from GH to the same extent as those with GHD due to NFPA.
- Published
- 2010
- Full Text
- View/download PDF
44. Effect of growth hormone replacement therapy on plasma brain natriuretic peptide concentration, cardiac morphology and function in adults with growth hormone deficiency.
- Author
-
Lazúrová I, Pura M, Wagnerová H, Tajtáková M, Sedláková M, Tomás L, Payer J, Hrúziková P, Vanuga P, Podoba J, Trejbalová L, Popovic V, and Koltowska-Häggström M
- Subjects
- Adult, Heart Ventricles pathology, Humans, Insulin-Like Growth Factor I analysis, Male, Middle Aged, Prospective Studies, Recombinant Proteins therapeutic use, Stroke Volume drug effects, Young Adult, Heart Ventricles physiopathology, Hormone Replacement Therapy, Human Growth Hormone deficiency, Human Growth Hormone therapeutic use, Natriuretic Peptide, Brain blood
- Abstract
Objective: The impact of growth hormone (GH) replacement on plasma brain natriuretic peptide (BNP) in association with cardiac morphology and function in adults with growth hormone deficiency (GHD) was evaluated., Subjects and Methods: Fifty nine adult patients with GHD (29 men, age 19-59 years) received a starting dose of 0.1-0.2 mg/day recombinant GH, which was subsequently adjusted to the 50th percentile of normal serum insulin-like growth factor (IGF-1) over a 6 month period. Plasma BNP and IGF-I levels before, 3 and 6 months after treatment were determined, as were the echocardiographic data, such as ejection fraction (EF), left ventricular end-diastolic volume (LVEDV), left ventricular end-diastolic diameter (LVEDD), interventricular septal thickness (IVST), posterior wall thickness (PWT), left ventricular mass (LVM), E/A wave and deceleration time (DT)., Results: Mean plasma BNP levels (53.1+/-8 pg/ml) and echocardiographic parameters were within the normal range at baseline, although men had higher LVM, IVST, PWT, LVEDV and LVEDD, respectively. A significant decrease in plasma BNP was observed after 6 months (27+/-5.6 pg/ml, P<0.05). No significant changes in echocardiographic parameters were observed except for a mild tendency to increase in LVM, and a borderline decrease in DT (181+/-8.1 vs. 155+/-9 ms, P<0.01)., Conclusions: Six months GH replacement therapy induced a significant decrease in plasma BNP levels despite the majority of patients having plasma BNP within the normal range at baseline. A borderline decrease in diastolic deceleration time was observed, the clinical significance of which is unclear., (J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart * New York.)
- Published
- 2010
- Full Text
- View/download PDF
45. Which patients with acromegaly are treated with pegvisomant? An overview of methodology and baseline data in ACROSTUDY.
- Author
-
Brue T, Castinetti F, Lundgren F, Koltowska-Häggström M, and Petrossians P
- Subjects
- Acromegaly blood, Acromegaly etiology, Acromegaly metabolism, Adolescent, Adult, Alanine Transaminase blood, Aspartate Aminotransferases blood, Biomarkers blood, Blood Glucose metabolism, Europe, Female, Glycated Hemoglobin metabolism, Growth Hormone-Secreting Pituitary Adenoma complications, Growth Hormone-Secreting Pituitary Adenoma metabolism, Hormone Antagonists administration & dosage, Hormone Antagonists adverse effects, Human Growth Hormone administration & dosage, Human Growth Hormone adverse effects, Human Growth Hormone therapeutic use, Humans, Insulin-Like Growth Factor I metabolism, International Cooperation, Internet, Liver Function Tests, Male, Middle Aged, Pituitary Neoplasms complications, Pituitary Neoplasms metabolism, Registries, Severity of Illness Index, United States, Young Adult, Acromegaly drug therapy, Hormone Antagonists therapeutic use, Human Growth Hormone analogs & derivatives, Receptors, Somatotropin antagonists & inhibitors
- Abstract
Context Pegvisomant (Somavert, Pfizer Inc.) is the first and only available GH receptor antagonist. ACROSTUDY is an international surveillance study that offers inclusion in a web-based registry to all patients with acromegaly treated with pegvisomant; it aims at monitoring long-term safety and efficacy of this compound. Patients and methods This report summarizes the main baseline characteristics of this particular population of patients. In February 2009, over 300 centres in 10 countries had contributed 792 patients. A gradual increase in cumulative patient recruitment was observed since the launching of ACROSTUDY in 2004: from 116 patients in 2005, it steeply increased to 792 at the latest data freeze in February 2009. At the time of enrolment, 91.8% of patients were already treated with pegvisomant but baseline was considered at the time of pegvisomant start. IGF1 concentrations were measured at local laboratories. Results Of all patients, 80% were reported to have had surgery and 33% to have received radiation therapy. Of the 792 patients, 14% had received no prior medical treatment before pegvisomant start, 65.9% had received somatostatin analogues and 18.6% dopamine agonists. Interestingly, 66.7% had received only pegvisomant at study start, while it was taken in association with dopamine agonists in 5.7%, with somatostatin analogues in 23.4% and with both types of agents in 3.8%. Mean IGF1 at baseline was 522 ng/ml. Conclusion Analysis of the baseline features of these patients treated with pegvisomant and reported in the ACROSTUDY database underscores the severity of the disease in this subset of the population of patients with acromegaly previously unresponsive to several medical, surgical or radiation treatment approaches.
- Published
- 2009
- Full Text
- View/download PDF
46. Assessment of quality of life in adult patients with GH deficiency: KIMS contribution to clinical practice and pharmacoeconomic evaluations.
- Author
-
Koltowska-Häggström M, Mattsson AF, and Shalet SM
- Subjects
- Adult, Age Factors, Aged, Biomarkers blood, Confounding Factors, Epidemiologic, Databases, Factual, Female, Health Resources statistics & numerical data, Human Growth Hormone economics, Humans, Hypopituitarism economics, Insulin-Like Growth Factor I metabolism, International Cooperation, Male, Middle Aged, Sex Factors, Drug Costs, Human Growth Hormone deficiency, Human Growth Hormone therapeutic use, Hypopituitarism drug therapy, Quality of Life
- Abstract
Quality of life (QoL) has emerged as an important construct that has found numerous applications across healthcare-related fields, ranging from research and clinical evaluation of treatment effects to pharmacoeconomic evaluations and global healthcare policy. Impairment of QoL is one of the key clinical characteristics in adult GHD and has been extensively studied in the Pfizer International Metabolic Database (KIMS). We provide summarized evidence on GH treatment effects for both clinical and health economic applications based on the KIMS data. The primary focus is on those aspects of QoL research that cannot be investigated in the traditional clinical trial setting, such as specific patient subgroups, cross-country comparisons and long-term follow-up. First, the impact of age, gender, disease onset, primary aetiology, extent of hypopituitarism, previous radiotherapy and obesity on QoL before and during long-term GH replacement is discussed. Secondly, the studies on QoL in relation to country-specific normative values are reviewed. Finally, health economic data derived from KIMS including both burden of disease and utility assessment are evaluated. We conclude that the wide spectrum of analyses performed on the KIMS data allows for practical application of the results not only to research and clinical practice but also to health policy and global medical decision making.
- Published
- 2009
- Full Text
- View/download PDF
47. GH replacement in hypopituitarism improves lipid profile and quality of life independently of changes in obesity variables.
- Author
-
Abrams P, Boquete H, Fideleff H, Feldt-Rasmussen U, Jönsson PJ, Koltowska-Häggström M, Wilton P, and Abs R
- Subjects
- Adult, Female, Humans, Hypopituitarism drug therapy, Hypopituitarism psychology, Longitudinal Studies, Male, Middle Aged, Obesity drug therapy, Obesity psychology, Hormone Replacement Therapy methods, Human Growth Hormone therapeutic use, Hypopituitarism blood, Lipids blood, Obesity blood, Quality of Life psychology
- Abstract
Objective: GH deficiency (GHD) in adults is characterized by elevated body mass index (BMI), increased waist girth (WG) and increased fat mass (FM). Information about how these indicators of obesity affect the lipid profile and quality of life (QoL) of GHD subjects is scarce. It is also unclear how changes in these indicators brought about by GH replacement influence lipids and QoL., Design and Methods: Adult GHD subjects from the Pfizer International Metabolic Database were grouped according to BMI (n=291 with BMI <25 kg/m(2), n=372 with BMI 25-30 kg/m(2), n=279 with BMI >30 kg/m(2)), WG (n=508 with normal WG, n=434 with increased WG) and FM (n=357) and according to changes in these variables after 1 year of GH replacement. Serum IGF-I concentrations, lipid concentrations and QoL using the QoL Assessment of GHD in Adults questionnaire were assessed at baseline and after 1 year of treatment., Results: At baseline, total and low-density lipoprotein (LDL) cholesterol were similarly elevated in the BMI and WG groups, but high-density lipoprotein (HDL) cholesterol decreased and triglycerides increased with increasing BMI and WG. QoL was progressively poorer with increasing BMI and WG. After 1 year of GH replacement, total and LDL cholesterol and QoL improved in all BMI, WG and FM groups., Conclusions: Variables of obesity adversely affect the already unfavourable lipid profile in GHD subjects by decreasing HDL cholesterol, but do not counteract the positive effect of GH replacement on LDL cholesterol. Similarly, QoL is influenced by obesity, but responds equally well to GH treatment independent of BMI, WG and FM.
- Published
- 2008
- Full Text
- View/download PDF
48. Impact of the primary aetiology upon the clinical outcome of adults with childhood-onset GH deficiency.
- Author
-
Hoybye C, Jönsson P, Monson JP, Koltowska-Häggström M, Hána V, Geffner M, and Abs R
- Subjects
- Adolescent, Adult, Body Height, Dwarfism, Pituitary drug therapy, Dwarfism, Pituitary etiology, Dwarfism, Pituitary psychology, Female, Humans, Hypopituitarism drug therapy, Hypopituitarism psychology, Male, Pituitary Neoplasms drug therapy, Pituitary Neoplasms etiology, Pituitary Neoplasms psychology, Quality of Life psychology, Retrospective Studies, Treatment Outcome, Human Growth Hormone deficiency, Human Growth Hormone therapeutic use, Hypopituitarism etiology
- Abstract
Objective: The impact of the aetiology of childhood-onset GH deficiency (CO-GHD) on the clinical presentation during adulthood and the response to GH replacement has been poorly defined. Our study aims to characterize CO-GHD in adults due to different aetiologies and evaluate the effect of 2 years of GH replacement therapy., Design and Methods: Data from 353 adults with CO-GHD from Pfizer International Metabolic Database KIMS were retrospectively grouped according to GHD aetiology: non-organic disorder (n=147), organic pituitary disease (n=159), and brain tumour (n=47). Extent of pituitary dysfunction, IGF-I concentration, lipid concentrations and quality-of-life (QoL) were assessed at baseline and after 2 years of GH replacement., Results: GHD was diagnosed at a later age in the organic pituitary group than in the other groups, resulting in a shorter duration of GH treatment during childhood. However, the final height was greater in the organic pituitary group. Panhypopituitarism was most common in the non-organic disorder and in the organic pituitary groups, while isolated GHD was more prominent in the brain tumour group. Serum IGF-I levels were the lowest in the non-organic group. QoL was the poorest in the brain tumour group. Lipid profile and QoL improved significantly during GH replacement., Conclusion: The adverse consequences of CO-GHD in adulthood vary between aetiologies, but improve similarly with GH treatment. It is, therefore, important to consider retesting all patients with CO-GHD in early adulthood and, if persistent severe GHD is confirmed, recommence GH replacement.
- Published
- 2007
- Full Text
- View/download PDF
49. Growth hormone (GH) replacement decreases serum total and LDL-cholesterol in hypopituitary patients on maintenance HMG CoA reductase inhibitor (statin) therapy.
- Author
-
Monson JP, Jönsson P, Koltowska-Häggström M, and Kourides I
- Subjects
- Case-Control Studies, Cholesterol, HDL blood, Databases, Factual, Drug Administration Schedule, Drug Industry, Drug Therapy, Combination, Female, Humans, Hypopituitarism blood, Insulin-Like Growth Factor I analysis, Male, Statistics, Nonparametric, Triglycerides blood, Cholesterol blood, Cholesterol, LDL blood, Human Growth Hormone therapeutic use, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Hypopituitarism drug therapy
- Abstract
Objective: Adult onset GH deficiency (GHD) is characterized by abnormalities of serum lipoprotein profiles and GH replacement results in favourable alterations in serum total and low density lipoprotein (LDL)-cholesterol. Preliminary evidence has indicated that the effect of GH replacement in this respect may be additive to that of HMG CoA reductase inhibitor (statin) therapy. We have examined this possibility during prospective follow-up of adult onset hypopituitary patients enrolled in KIMS (Pfizer International Metabolic Database), a pharmacoepidemiological study of GH replacement in adult hypopituitary patients., Design: Lipoprotein profiles were measured centrally at baseline and after 12 months GH replacement therapy., Patients: Sixty-one hypopituitary patients (30 male, 31 female) on maintenance statin therapy (mean 2.5 +/- 2.7 SD years before GH) (statin group - SG) and 1247 (608 male, 639 female) patients not on hypolipidaemic therapy (nonstatin group - NSG) were studied. All patients were naïve or had not received GH replacement during the 6 months prior to study. Patients who developed diabetes mellitus during the first year of GH therapy or in the subsequent year and those with childhood onset GHD were excluded from this analysis. An established diagnosis of diabetes mellitus was present in 18% SG and 4.4% NSG at baseline., Measurements: Serum concentrations of total, high density lipoprotein (HDL)-cholesterol, triglycerides and IGF-I were measured centrally in all patients and LDL-cholesterol was estimated using Friedewald's formula., Results: The relative frequency of various statin use was simvastatin 52% (15.8 +/- 8.1 mg, mean +/- SD), atorvastatin 30% (14.4 +/- 7.8 mg), pravastatin 9.8% (31.6 mg +/- 13.9 mg), lovastatin 6.6% (17.5 +/- 5 mg) and fluvastatin 1.6% (40 mg). Baseline serum total and LDL-cholesterol (mean +/- SD) were 5.2 +/- 1.4 and 3.1 +/- 1.3 mmol/l in SG and 5.8 +/- 1.2 and 3.7 +/- 1.0 mmol/l in NSG, respectively (P < 0.0001, SG vs. NSG). After 12 months GH replacement (SG: 0.32 +/- 0.17 mg/day; NSG: 0.38 +/- 0.1 mg/day) serum total and LDL-cholesterol decreased by a mean (+/-SD) of 0.48 (+/- 1.25) mmol/l (P < 0.0004) and 0.53 (+/- 1.08) mmol/l (P < 0.0001) in SG and by 0.30 (+/- 0.89) mmol/l (P < 0.0001) and 0.28 (+/- 0.80) mmol/l (P < 0.0001) in NSG, respectively. There were no significant changes in HDL-cholesterol or triglycerides in either group (SG vs. NSG: NS). A relationship between LDL-cholesterol at baseline and the decrease in LDL-cholesterol after 12 months GH was evident in both groups (SG: R = -0.54, P < 0.001; NSG: R = -0.4, P < 0.001) and a similar relationship for cholesterol was observed., Conclusions: These data indicate that GH replacement exerts additional beneficial effects on lipoprotein profiles in patients on maintenance statin therapy, confirming that the effects of these interventions are complementary rather than exclusive.
- Published
- 2007
- Full Text
- View/download PDF
50. Growth hormone (GH) replacement therapy in GH deficient adults: predictors of one-year metabolic and clinical response.
- Author
-
Svensson J, Finer N, Bouloux P, Bevan J, Jonsson B, Mattsson AF, Lundberg M, Harris PE, Koltowska-Häggström M, and Monson JP
- Subjects
- Cohort Studies, Dose-Response Relationship, Drug, Dwarfism, Pituitary metabolism, Female, Follow-Up Studies, Humans, Male, Middle Aged, Models, Statistical, Prognosis, Quality of Life, Sex Characteristics, Treatment Outcome, Dwarfism, Pituitary diagnosis, Dwarfism, Pituitary drug therapy, Growth Hormone therapeutic use, Hormone Replacement Therapy
- Abstract
Objective: This study investigated whether baseline status could predict the responsiveness to one-year growth hormone (GH) replacement therapy in adult GH deficient (GHD) patients., Design: A total of 380 European patients with adult onset GHD due to non-functioning pituitary adenoma that had been enrolled in Pfizer International Metabolic Database (KIMS), and that had completed one year of GH replacement therapy within KIMS, were studied., Results: The mean initial dose of GH was 0.22 (SEM 0.01) mg/day and after one year, the mean dose was 0.36 (0.01) mg/day. The mean insulin-like growth factor-I (IGF-I) SD score increased from -1.75 (0.08) at baseline to 0.47 (0.05) after one year. Quality of life (QoL)-Assessment of GHD in Adults (QoL-AGHDA), waist circumference, waist:hip ratio, and serum lipid pattern improved. Women received a higher dose of GH than men after one year, and demonstrated similar treatment response. In multiple stepwise forward regression analyses, the one-year changes in QoL-AGHDA score, waist:hip ratio, and serum low density lipoprotein-cholesterol (LDL-C) level correlated inversely with the baseline values of the same variable. In addition, the change after one year in QoL-AGHDA score correlated inversely with duration of hypopituitarism and baseline serum high density lipoprotein-cholesterol (HDL-C) level, and the change in waist:hip ratio correlated inversely, although more weakly, with baseline serum HDL-C level and UK citizenship and positively with baseline waist circumference and the initial GH dose. The change in serum LDL-C level additionally correlated inversely with the mean GH dose and duration of hypopituitarism and positively with UK citizenship., Conclusions: Baseline status could, with moderate strength, predict the responsiveness in the same variable whereas it could not, or only weakly, predict the response in other variables. Therefore, when the decision to start GH replacement is undertaken, as many outcome variables as possible should be evaluated in order to adequately evaluate the likelihood of clinical benefit. Finally, women have a similar response to GH replacement as men when individualised GH dosing schedules are employed and should therefore be selected for GH therapy to a similar extent.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.